SAB Biotherapeutics, Inc. Common Stock (SABS) Stock Price

SABSStock

$3.81+64.96%52W

Market Cap$346.66M

P/E25.91x

PEG Ratio—

Div yield—

Beta0.60

SABS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-14.45%

Price vs S&P 500 (4W)1.88%

VGM Score34.70

P/E Ratio (Annual)25.91x

Book Value / Share (Quarterly)$2.57

P/TBV (Annual)1.52x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-72.10%

Cash Flow / Share (Quarterly)$-0.69

Price vs S&P 500 (YTD)-15.17%

Net Profit Margin (TTM)-1795.85%

EPS (TTM)$-1.42

10-Day Avg Trading Volume0.35M

EPS Excl Extra (TTM)$-1.42

EPS (Annual)$0.22

ROI (Annual)8.58%

Net Profit Margin (5Y Avg)-906.73%

Cash / Share (Quarterly)$1.23

P/E Basic Excl Extra (TTM)25.91x

EPS Growth (5Y)-50.72%

P/E Normalized (Annual)25.91x

ROA (Last FY)7.68%

Revenue Growth TTM (YoY)-92.42%

EBITD / Share (TTM)$-1.35

ROE (5Y Avg)-60.20%

Operating Margin (TTM)-2388.92%

Cash Flow / Share (Annual)$-0.96

P/B Ratio1.60x

P/B Ratio (Quarterly)1.39x

Net Income / Employee (Annual)$154,300

EV / Revenue (TTM)256.16x

Net Interest Coverage (TTM)-52.02x

ROA (TTM)12.51%

EV / EBITDA (TTM)22.33x

EPS Incl Extra (Annual)$0.22

Current Ratio (Annual)9.46x

Quick Ratio (Quarterly)8.93x

3-Month Avg Trading Volume0.74M

52-Week Price Return64.96%

P/E Incl Extra (TTM)25.91x

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.29

P/S Ratio (Annual)260.08x

Asset Turnover (Annual)0.03x

52-Week High$5.15

Operating Margin (5Y Avg)-1010.02%

EPS Excl Extra (Annual)$0.22

CapEx CAGR (5Y)-40.71%

26-Week Price Return-3.21%

Quick Ratio (Annual)9.13x

13-Week Price Return-4.99%

Total Debt / Equity (Annual)0.02x

Current Ratio (Quarterly)9.22x

Enterprise Value$338.86M

Asset Turnover (TTM)0.02x

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-2579.03%

Cash / Share (Annual)$2.03

3-Month Return Std Dev53.10%

Net Income / Employee (TTM)$154,300

EBITDA CAGR (5Y)-9.83%

ROE (Last FY)8.76%

Net Interest Coverage (Annual)-80.07x

EPS Basic Excl Extra (Annual)$0.22

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.01x

EPS Incl Extra (TTM)$-1.42

Receivables Turnover (Annual)0.00x

ROI (TTM)14.61%

P/S Ratio (TTM)259.99x

Pretax Margin (5Y Avg)-906.71%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.62

Price vs S&P 500 (52W)46.65%

P/E Ratio (TTM)25.91x

Year-to-Date Return-3.21%

5-Day Price Return-4.49%

EPS Normalized (Annual)$0.22

ROA (5Y Avg)-35.54%

Net Profit Margin (Annual)-2579.03%

Month-to-Date Return1.40%

Cash Flow / Share (TTM)$-0.47

EBITD / Share (Annual)$-0.79

Operating Margin (Annual)-3244.87%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-53.03%

P/E Excl Extra (TTM)25.91x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.42

P/TBV (Quarterly)3.09x

P/B Ratio (Annual)1.18x

Pretax Margin (TTM)-1795.85%

Book Value / Share (Annual)$3.18

Price vs S&P 500 (13W)-7.78%

Beta0.60x

Revenue / Share (TTM)$0.00

ROE (TTM)15.17%

52-Week Low$1.85

vGradeD

gGradeF

mGradeB

vgmGradeD

SABS Earnings Surprise History

Q2 25-1.09est. -0.80

Q3 250.50est. -0.46

Q4 25-0.41est. -0.17

Q2 26-0.28est. -0.28

SABS Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.29

4.38

4.35

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
SABSSAB Biotherapeutics, Inc. Common Stock	D	F	B	$3.81
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About SAB Biotherapeutics, Inc. Common Stock

SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing targeted human polyclonal antibodies using its DiversitAb platform, which leverages genetically engineered cattle to produce large quantities of fully human antibodies without human plasma or serum. This differentiated approach enables rapid, scalable production for therapeutic applications.